Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.

Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data were not released.

A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.

[4] Immune activation: Dostarlimab Other: Ibalizumab This monoclonal antibody–related article is a stub.

You can help Wikipedia by expanding it.This antineoplastic or immunomodulatory drug article is a stub.